Literature DB >> 3741316

Morphological and clinical significance of cell kinetics in non-Hodgkin's lymphomas.

G Del Bino, R Silvestrini, A Costa, S Veneroni, R Giardini.   

Abstract

The relation between the proliferative activity and morphologic features according to Rappaport and Kiel classifications and the Working Formulation (WF) was analyzed in a series of 123 adult patients with non-Hodgkin lymphomas. Cell kinetics was determined as in vitro 3H-thymidine labelling index (LI). A significant association was observed between low LI and follicular histology or low grade of the WF, as well as between high LI and high-grade of malignancy of the Kiel and WF. The analysis of the clinical relevance of cell kinetics on objective response to treatment showed a higher frequency (91%) of complete remission in the tumors with low proliferative activity versus tumors with high proliferative activity (48%) (p = 0.00003). Moreover, cell kinetics proved to be and important indicator of 6-year survival on the whole population of patients (66% for slowly vs 18% for fast-proliferating tumors; p less than 10(-9)) and a further discriminant within diffuse histology (68% vs 9%; p less than 0.0001), low-grade malignancy according to the Kiel (64% vs 15%; p less than 10(-8)) and low (64% vs 28%; p less than 0.005) and intermediate grades of the WF (68% vs 9%; p less than 0.0001).

Entities:  

Mesh:

Year:  1986        PMID: 3741316

Source DB:  PubMed          Journal:  Basic Appl Histochem        ISSN: 0391-7258


  2 in total

1.  Reversing effect of Tanshinone on malignant phenotypes of human hepatocarcinoma cell line.

Authors:  Shu-Lan Yuan; Ren-Min Huang; Xiu-Jie Wang; Yi Song; Guang-Qi Huang
Journal:  World J Gastroenterol       Date:  1998-08       Impact factor: 5.742

2.  Prognostic value of cytophotometric analysis of DNA in lymph node aspirates from patients with non-Hodgkin's lymphoma.

Authors:  J Vucković; M Dubravcić; J M Matthews; S N Wickramasinghe; M Dominis; B Jaksić
Journal:  J Clin Pathol       Date:  1990-08       Impact factor: 3.411

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.